Stock Financial Ratios, Dividends, Split History

DISCB / Discovery Communications, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)4,252.51
Enterprise Value ($M)24,352.49
Book Value ($M)7,889.00
Book Value / Share50.55
Price / Book1.25
NCAV ($M)-20,124.00
NCAV / Share-128.95
Price / NCAV-0.21
Share Statistics
Common Shares Outstanding2 6,512,379
Common Shares Outstanding3 219,782,537
Common Shares Outstanding 155,613,008
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.02
Return on Assets (ROA)-0.02
Return on Equity (ROE)-0.06
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio1.83
Income Statement (mra) ($M)
Distribution Revenue3,474,000,000.00
Equity Method Investment Summarized Financial Information Revenue1,780,000,000.00
Other Sales Revenue Net326,000,000.00
Sales Revenue Net6,873,000,000.00
Advertising Revenue3,073,000,000.00
Revenue From Related Parties667,000,000.00
Operating Income713.00
Net Income-313.00
Cash Flow Statement (mra) ($M)
Cash From Operations1,629.00
Cash from Investing-633.00
Cash from Financing1,629.00
Identifiers and Descriptors
Central Index Key (CIK)1437107

Split History

Stock splits are used by Discovery Communications, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Nasdaq Composite Closes at Record High: 5 Top-Ranked Picks

2018-06-15 zacks
On Jun 14, the tech-heavy Nasdaq Composite index scaled a fresh high at closing. Yesterday’s rally can be attributed to strong showing by media, telecom and tech stocks fueled by market anticipation of mega merger deals. This also highlights the gradual fading of investors’ apprehensions regarding the trade and geopolitical issues, which was the primary reason behind severe market volatility in the last three months. (217-0)

With or Without Time Warner, AT&T Stock Isn't Worth Buying | InvestorPlace

2018-06-13 investorplace
The acquisition of Time Warner Inc (NYSE:TWX) by AT&T Inc. (NYSE:T) appears to be a go. And the approval of the AT&T-TWX merger, announced Tuesday afternoon, already is reverberating through the market. (248-0)

Corporate round-up: Aegon Life appoints Saba Adil as Chief Operating Officer

2018-06-11 moneycontrol
Aegon Life Insurance has appointed Saba Adil as the new chief operating officer, effective May 1. (29-0)

Discovery Communications (DISCA) Down 5.7% Since Earnings Report: Can It Rebound?

2018-06-07 zacks
A month has gone by since the last earnings report for Discovery Communications, Inc. (DISCA - Free Report) . Shares have lost about 5.7% in that time frame. (51-0)

How Facebook Let Gadgets Tap Your Data: DealBook Briefing - The New York Times

2018-06-04 nytimes
The technology giant struck data-sharing partnerships with at least 60 device makers — including Amazon, Apple, BlackBerry, Microsoft and Samsung — over the last decade. The company claimed that those deals were supposed to make it easier for people to use Facebook before its app was widely available on smartphones. But an NYT investigation found that the deals provided wide-ranging access to user data, and that many arrangements still exist, even though Facebook said that it had cut such off third-party access in 2015. (122-0)